latest news releases from the newsroom
Infinity Pharmaceuticals, Inc.
Infinity and MedImmune Present Preliminary Phase 1 Data Demonstrating Biological Activity of IPI-504, A Novel Hsp90 Inhibitor, in Advanced Non-Small Cell Lung Cancer
CAMBRIDGE, Mass. and GAITHERSBURG, Md., Oct. 25, 2007 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) and MedImmune, Inc. today announced preliminary results of an ongoing Phase 1/2 clinical trial of IPI-504, the companies' lead heat shock protein 90 (Hsp90) inhibitor, in patients with advanced non-small cell lung cancer (NSCLC). Seven of nine evaluable patients receiving IPI-504 achieved disease stabilization over at least one cycle of administration, and four of four evaluated patients who underwent positron emission tomography (PET) imaging exhibited a decrease in tumor metabolic activity in response to IPI-504 administration. The data were presented yesterday at the American Association for Cancer Research-National Cancer Institute-European Organization for Research and Treatment of Cancer (EORTC) International Conference on Molecular Targets and Cancer Therapeutics in San Francisco.
Zecotek Photonics Inc.
Zecotek's Patented LFS Scintillation Crystals Selected For Trials by the Paul Scherrer Institute, Switzerland
VANCOUVER, British Columbia, Oct. 25, 2007 (PRIME NEWSWIRE) -- Zecotek Medical Systems Inc. (TSX-V:ZMS) (Frankfurt:W1I) today announced the Paul Scherrer Institute based in Switzerland has purchased an order of Zecotek's patented Lutetium Fine Silicate (LFS) scintillation crystals for trials in its next-generation Positron Emission Tomography (PET) medical imaging program. The Paul Scherrer Institute PET program is focused on advancing improvements in sensitivity, spatial resolution and image quality in PET scanners, based on the understanding that advances in PET are driven largely by progress in instrumentation, in particular the performance of scintillation materials, photo-detectors and read-out electronics. Higher resolution PET scanners would also widen PET's application in brain function analysis and diagnosis.
BioForce Nanosciences Holdings, Inc.
BioForce Nanosciences Holdings, Inc. Announces Notice of Allowance for Its Sindex Chip Patent
AMES, Iowa, Oct. 25, 2007 (PRIME NEWSWIRE) -- BioForce Nanosciences Holdings, Inc. (OTCBB:BFNH), a company focused on the development and commercialization of nanotech tools and solutions for the life sciences, announced today that it has received Notice of Allowance from the United States Patent Office for Sindex(tm) chips. Sindex(tm) chips are indexed silicon substrates that serve as the basis for a host of ultraminiaturized molecular tests. As an example, BioForce researchers have developed a cancer biomarker screen that requires only four cells using the Sindex(tm) chip. They are the perfect complement to the BioForce Nano eNabler(tm) bench top molecular printer because their indexing system allows users to map the locations of microscopic biological test sites and easily find them for analysis. The Nano eNabler(tm) is being used at elite academic institutions around the world such as Harvard Medical School and Johns Hopkins University for research and development of novel nanotech applications.